Yorhe(SZ:002795)2023-04-28 16:00Financial Performance - The company's operating revenue for 2022 was ¥989,736,616.68, a decrease of 1.86% compared to ¥1,008,508,895.38 in 2021[6]. - The net profit attributable to shareholders was -¥26,703,315.88 in 2022, representing a decline of 242.93% from ¥18,682,917.51 in 2021[6]. - The net profit after deducting non-recurring gains and losses was -¥23,236,427.00, down 258.01% from ¥14,705,244.35 in the previous year[6]. - The total profit amounted to -10.07 million yuan, representing a decline of 127.63% year-on-year[56]. - Total revenue for 2022 was approximately ¥989.74 million, a decrease of 1.86% compared to ¥1,008.51 million in 2021[76]. - The industrial segment revenue decreased by 8.22% to ¥842.85 million, while medical services and other industries saw a significant increase of 62.87% to ¥146.89 million[76]. - The company reported a net profit of -29,419,229.42 yuan for the year 2022, resulting in a total distributable profit of 57,288,351.36 yuan[182]. - The cash dividend total for the reporting period was 0 yuan, reflecting the company's negative net profit and lack of distributable profit[181]. Cash Flow and Assets - The net cash flow from operating activities increased by 83.67% to ¥211,517,475.65, compared to ¥115,162,707.14 in 2021[6]. - The total assets at the end of 2022 were ¥1,548,725,920.03, an increase of 2.80% from ¥1,506,596,737.33 at the end of 2021[6]. - Cash and cash equivalents increased by 767.10% to CNY 171,556,346.50 from CNY 19,785,081.83 in 2021[92]. - Cash and cash equivalents represented 21.51% of total assets, up from 8.76% at the beginning of the year, indicating improved liquidity[96]. - The company's fixed assets decreased by 2.30% to CNY 432,974,178.84 from CNY 455,901,734.73 in the previous year[96]. Business Operations and Strategy - The company operates in various sectors, including medical technology and fluid control systems[19]. - The company is expanding into the photovoltaic battery industry while continuing to develop its tumor precision radiotherapy and valve plumbing businesses[33]. - The company has established a chain of specialized hospitals for tumor precision radiotherapy, with advanced medical imaging and treatment equipment[46]. - The company plans to expand its tumor precision radiotherapy services and improve treatment capabilities in response to market demands[51]. - The company aims to improve patient satisfaction and service quality through comprehensive healthcare management and service reforms[57]. - The company is strategically focusing on high-value cities and emerging markets to expand its chain of specialized hospitals in cancer treatment[62]. - The company plans to enter the photovoltaic manufacturing sector, focusing on high-efficiency N-type TOPCon battery production and expanding its market share in large-scale solar projects[115]. Research and Development - Research and development expenses rose by 19.47% to ¥22.35 million, reflecting the company's commitment to innovation[85]. - The company has developed 57 intellectual property rights related to TOPCon and IBC battery technologies, enhancing its competitive edge in the photovoltaic sector[71]. - The number of R&D personnel increased by 16.30% from 92 in 2021 to 107 in 2022, with R&D personnel accounting for 8.09% of the total workforce[90]. - R&D investment increased by 19.47% from ¥18,710,677.24 in 2021 to ¥22,353,952.01 in 2022, representing 2.26% of operating revenue[91]. Corporate Governance - The company has established a fair and transparent performance evaluation and incentive mechanism for directors and senior management, enhancing operational efficiency[135]. - The company maintains independence from its controlling shareholder in business, personnel, assets, and finance, ensuring no competitive conflicts exist[131]. - The company has a complete and independent business system, capable of making autonomous operational decisions without reliance on the controlling shareholder[141]. - The company has implemented a strict insider information management system, with no violations reported during the reporting period[138]. - The company has established a robust internal control system, including internal audit regulations, to ensure compliance and financial decision-making independence[145]. Market Trends and Challenges - The demand for tumor medical services is expected to grow, with an estimated 499,000 new cancer cases projected in China by 2024[34]. - The market size for precision radiotherapy in China reached 37.5 billion CNY in 2021, with a CAGR of 15.6% from 2016 to 2021, expected to grow to 80.9 billion CNY by 2025[36]. - The company anticipates increased competition in the solar energy sector, which may pressure its market expansion and project profitability[124]. - The photovoltaic industry is experiencing a phase of structural overcapacity, with leading companies accelerating capacity expansion to maintain market share[125]. Employee and Talent Management - The total number of employees at the end of the reporting period was 1,322, with 1,309 from major subsidiaries[174]. - The company emphasizes internal talent development and has established a comprehensive training plan to enhance employee capabilities[177]. - The company has implemented a differentiated compensation model based on employee levels and categories[175]. - The company ensures that employee income growth aligns with overall company performance to maintain cost control[176]. Shareholder Engagement - The company has established a three-year shareholder return plan (2022-2024) to ensure a scientific, sustainable, and stable return mechanism for shareholders[179]. - The company is committed to ensuring that minority shareholders' rights are fully protected and that the decision-making process for dividends is transparent and compliant[180]. - The company held several shareholder meetings in 2022, with participation rates ranging from 4.37% to 25.95%[147].